Almirall (0O9B)
London Exchange · UK · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 10.38 |
|---|---|
| 52-week range | 9.88 – 13.98 |
| Return, 1 month / 3 months | +0.0% / −6.6% |
| Return, 1 year / 3 years | −13.6% / +21.5% |
| Trend | Below its 200-day average |
| RSI (14) | 53 |
| Volatility (1 year) | 24.9% |
| Worst drawdown (1 year) | -27.7% |
| Average daily value traded | 0.25M EUR |
| Dividend yield | 1.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Almirall is a pharmaceutical company based in Barcelona, Spain, that concentrates on skin health. It develops and markets prescription medicines for dermatological conditions, including treatments for psoriasis, acne and other inflammatory skin disorders. Its customers are mainly dermatologists, hospitals and healthcare systems, and it also sells some respiratory and gastrointestinal products. The company researches, licenses and commercialises its medicines across Europe and other markets.
Almirall trades under the code 0O9B on the London Exchange in UK, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Almirall (0O9B) trades on the London Exchange in UK. It last closed at EUR 10.38 on 23 October 2026.
Its price-based Market X-Ray is 39 out of 100 (a weak price profile), ranking 2,671 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 13.6% and over the last three months it fell 6.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 28 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -9.5% | ||
| From 52-week high | -25.0% | ||
| Momentum | 28 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -6.6% | ||
| 6-month return | -17.7% | ||
| 12-month return, skipping the last month | -13.6% | ||
| Stability (higher is calmer) | 65 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 24.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -27.7% | ||
| Liquidity | 39 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.25M EUR | ||
| Zero-volume days | 10.0% | ||
| Income | 32 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.5% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | +3.0% |
|---|---|
| 1 month | +0.0% |
| 3 months | −6.6% |
| 6 months | −17.7% |
| 1 year | −13.6% |
| 3 years | +21.5% |
| 5 years | −12.7% |
Signals
| 50-day / 200-day average | 10.34 / 11.48 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.70 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 14 May 2026 | EUR 0.1515 |
| 15 May 2025 | EUR 0.1490 |
| 17 May 2024 | EUR 0.1490 |
| 12 May 2023 | EUR 0.1490 |
| 13 May 2022 | EUR 0.1507 |
| 14 May 2021 | EUR 0.1499 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.